T he clinical presentation of aspiration syndromes falls within a wide spectrum ranging from subclinical manifestations such as dry cough or dysphonia to rapidly progressing disease such as the acute respiratory distress syndrome. The two most common consequences resulting from aspiration of gastric or oropharyngeal content are chemical pneumonitis and bacterial aspiration pneumonia. Both entities present with comparable clinical signs and symptoms. In the absence of a reliable marker to differentiate between these two conditions, most patients with suspected aspiration are treated empirically with antimicrobial agents. The widespread and often unnecessary use of antibiotics in these instances is fueling a wave of emerging drug-resistant bacteria.
The use of biomarkers has been suggested as a possible tool to distinguish chemical aspiration pneumonitis from bacterial aspiration pneumonia. Procalcitonin (PCT) is a 116 amino acid peptide with a sequence identical to that of prohormone of calcitonin but devoid of hormonal activity. Because PCT determination was first performed by Assicot et al (1) to differentiate between bacterial and nonbacterial causes of sepsis, it has become a marker of bacterial infection and used to provide rapid evidence of bacterial origin of shock or respiratory illness. Furthermore, the finding that PCT is released into the circulation within 3 hrs after endotoxin injection, plateaus at 6 hrs, and remains elevated for 24 hrs makes PCT a promising new agent for early and sensitive identification of severe infection (2) . Recently, PCT has been used to shorten duration of antibiotic therapy in patients hospitalized with community-acquired pneumonia and sepsis (3) (4) (5) (6) (7) (8) (9) . However, PCT can be increased in noninfectious conditions (10, 11) and may remain low in bacterial infections (12, 13) . There are relatively few data available on the use of PCT in patients with aspiration syndromes. Therefore, we investigated the use of plasma levels of PCT to differentiate between aspiration pneumonia and aspiration pneumonitis.
MATERIALS AND METHODS
Study Design. A prospective, outcome blind observational study was performed in the intensive care unit of a tertiary university teaching hospital between September 2007 and December 2009. The study was approved by the ethical committee of the hospital and informed consent was obtained from all participants or their healthcare proxy. Some of the patients were part of a previous investiga-Objective: To assess the predictive accuracy of serum procalcitonin in distinguishing bacterial aspiration pneumonia from aspiration pneumonitis.
Design: Prospective observational study. Setting: Intensive care unit of a university-affiliated hospital.
Patients: Sixty-five consecutive patients admitted with pulmonary aspiration and seven control subjects intubated for airway protection.
Interventions: None. Measurements and Main Results: Quantitative cultures from bronchoalveolar lavage fluid were conducted on all participants at the time of admission. Serial serum procalcitonin levels were measured on day 1 and day 3 using the procalcitonin enzymelinked fluorescent assay. There were no differences in the median serum concentrations of procalcitonin between patients with positive bronchoalveolar lavage cultures (n ‫؍‬ 32) and patients with negative bronchoalveolar lavage cultures (n ‫؍‬ 33) on either day 1 or day 3 postadmission. The areas under the receiver operator characteristic curves were 0.59 (95% confidence interval, 0.47-0.72) and 0.63 (95% confidence interval, 0.5-0.75), respectively (p ‫؍‬ .74). However, duration of mechanical ventilation and antibiotic therapy were shorter in those who had a decrease in their procalcitonin levels on day 3 from baseline compared with those who did not (6.7 ؎ 7.1 days and 11. (14) . All patients who were admitted with the following criteria were considered for enrollment: 1) the presence of risk factors for aspiration; 2) symptoms and signs suggestive of lower respiratory tract pathology; 3) new radiographic infiltrate on chest roentgenogram; and 4) need for mechanical ventilation. Exclusion criteria included: 1) discharge from a hospital within the prior 10 days; 2) an episode of pneumonia within the past 30 days; 3) prior antibiotics; 4) documented bacteremia; 5) chronic mechanical ventilation; 6) immunosuppressive therapy; 7) positive HIV antibody titer; and 8) postcardiopulmonary arrest. A control group devoid of underlying inflammatory disorders who were intubated for airway protection was included.
Data Collection. Demographic data collected included age, gender, comorbid illnesses, and the Charlson Index (15) . Clinical data were obtained on intensive care unit admission and comprised of clinical symptoms, daily vital signs, laboratory and radiographic data, and the Acute Physiology and Chronic Health Evaluation score (16) . The duration of mechanical ventilation, the length of stay, and the outcome (death or discharge) were also recorded. Drug selection and final decision about stopping antibiotics were at the treating physician's discretion.
Biological Samples. A bronchoalveolar lavage (BAL) was performed on all participants within 6 hrs of hospital admission. Samples for microbiologic analysis were processed as described previously (17) . Pneumonia was considered present when at least one pathogenic bacteria grew at concentration Ն10 4 colony-forming units/mL. For all patients, serum from blood drawn daily for routine biologic tests was collected on day 1 and on day 3 of hospitalization. Samples were frozen immediately after blood was drawn and then stored at Ϫ80°C. Assays were performed in batches at the end of the study period. Procalcitonin was measured using the bioMerieux's VIDAS BRAHMS PCT assay (Biomerieux, Durham, NC). The assay has a functional assay sensitivity of 0.09 ng/mL and a coefficient of variation of 6.2% at a mean concentration of 1.33 ng/mL and 6.4% at a mean concentration of 13.2 ng/mL All PCT measurements were performed in duplicate, and the mean of these duplicate results was considered.
Statistical Analysis. Data are expressed as means Ϯ SD unless specified otherwise. Categorical variables were compared using chisquared and Fisher's exact tests when appropriate. Comparison of numerical and categorical variables was performed with unpaired t tests or Mann-Whitney U tests when the latter were dichotomous, and analysis of variance or Kruskal-Wallis H-tests were carried out for variables with more than two categories. Correlation was assessed using Spearman's rank test. Cook's distance was used to assess for potential outliers. Values Ͼ1 were considered influential. To examine the univariate effects of patients' clinical characteristics and physiological variables on unfavorable outcome, a logistic regression model was used to test each characteristic. Risk factors with p values of Յ.10 in our univariate analysis were entered into the multivariate model. Interactions were tested in the model; variables strongly associated with another(s) were not included in the multivariate analysis. For all analysis, a two-tailed p value Ͻ.05 was considered statistically significant.
RESULTS
Sixty-five consecutive patients with clinical suspicion for aspiration and seven control subjects were enrolled. All patients were intubated in the emergency department and were hemodynamically stable on admission to the intensive care unit. The mean age of the study population was 57.3 Ϯ 20.7 yrs. The main underlying causes for aspiration were neurodegenerative disorders (n ϭ 24), drug overdose (n ϭ 15), cerebrovascular accident (n ϭ 14), and seizure (n ϭ 11). The characteristics of the study population are shown in Table 1 . Patients with pulmonary aspiration were older, had a higher burden of comorbidities, and were more severely ill than the control group.
Microbiologic analysis of the BAL fluid confirmed the presence of pneumonia in 32 cases. The microbial etiology of aspiration pneumonia is shown in Table 2 . Staphylococcus aureus and Escherichia coli were the predominant pathogens isolated. Table 3 displays the clinical characteristics between patients with BALpositive and BAL-negative cultures. All participants received a parenteral antimicrobial coverage consisting of ampicillin/ clavulanic acid plus a macrolide (n ϭ 29), a quinolone plus clindamycin (n ϭ 17), or vancomycin plus ciprofloxacin plus piperacillin/tazobactam (n ϭ 19).
Diagnostic Value of PCT. The differences in the plasma levels of PCT among the three groups (positive BAL culture, negative BAL culture, and control) on day 1 of aspiration were statistically significant (p Ͻ .001 by analysis of variance) with the highest values corresponding to patients with culture-negative BAL samples. However, there was no significant difference in PCT levels when comparing patients with culture-positive and culture-negative BAL specimens (p ϭ .17) (Fig. 1) .
There was also no correlation between alveolar arterial gradient, PaO 2 /FIO 2 , or extent of radiographic disease and serum PCT levels (p ϭ .42, p ϭ .66, and p ϭ .8, respectively). No correlation was found also between the species type and quantity of microorganisms cultured in the BAL fluid and the serum levels of PCT. On day 1 of aspiration, no best cutoff PCT value for the diagnosis of aspiration pneumonia could be established. Using a threshold of 2.0 ng/mL yielded a sensitivity of 76%, specificity of 38%, positive predictive value of 56%, and a negative predictive value of 60% (Table 4 ). The median serum PCT concentration values obtained on day 3 did not change significantly from day 1 for all three groups (Fig. 1) . The predictive ability of PCT to differentiate between culture-positive pulmonary aspiration and culture-negative pulmonary aspiration was assessed using the receiver operator characteristic curves on day 1 and day 3 (Fig. 2) . The areas under the receiver operator characteristic curves were 0.59 (95% confidence interval [CI], 0.47-0.72) and 0.63 (95% CI, 0.5-0.75), respectively (p ϭ .74).
Outcome. The inhospital mortality rates for BAL culture-positive and culture-negative groups were 36% and 28%, respectively (p ϭ .85). On day 3, the median serum PCT concentrations were significantly higher in patients whose outcomes would be unfavorable (4.20 [interquartile range, 2.98 -5.60] ng/mL) than in those with subsequent favorable outcome (1.84 [interquartile range, 1.10 -3.79] ng/mL) (p ϭ .001) (Fig. 3) . A procalcitonin cutoff value of 2 ng/mL on day 1 had a sensitivity of 77% (95% CI, 62-89%) and a specificity of 47% (95% CI, 26 -70%) in predicting survival with an area under the receiver operator characteristic curve of 0.62 (95% CI, 0.48 -0.73). A PCT threshold of 2 ng/mL on day 3 had a sensitivity of 86% (95% CI, 64 -97%) and a specificity of 52% (95% CI, 37-68%) with an area under the receiver operator characteristic curve of 0.76 (95% CI, 0.67-0.88) (Fig. 4) .
Duration of mechanical ventilation and length of intensive care unit stay were also shorter in those who had a drop in serum PCT levels in day 3 compared with day 1 (6.7 Ϯ 7.1 days and 11.1 Ϯ 13.5 days vs. 10.3 Ϯ 12.6 days and 14.3 Ϯ 11.2 days, respectively) (p ϭ .03 and p ϭ .02). There was also a significant difference in the duration of antimicrobial therapy between those patients who had a decline in PCT and those who did not (8.2 Ϯ 2.6 days vs. 12.8 Ϯ 4.6 days; p Ͻ .001). Logistic regression analysis identified radiographic multilobar disease on admission (adjusted odds ratio [OR], 1.14; 95% CI, 1.01-1.31; p ϭ .04) and a one-unit increase in PCT levels between day 1 and day 3 (adjusted OR, 5.63; 95% CI, 1.56 -20.29; p ϭ .008) as independent predictors of hospital mortality.
DISCUSSION
The results of this study indicate that serum PCT was not a good indicator of bacterial aspiration pneumonia. A drop in the serum PCT levels between day 1 and day 3 predicted a favorable outcome in pulmonary aspiration syndromes. This is the largest study to assess the use of serum PCT levels in pulmonary aspiration syndromes. Currently, the diagnosis of pulmonary aspiration is established by history and presence of underlying factors. This approach is severely limited by the fact that the clinical presentation and the laboratory workup would not distinguish aspiration pneumonitis from aspiration pneumonia. Our findings reaffirm this conclusion. Nylen and colleagues (18) were the first to study the kinetics of serum calcitonin in 12 patients with infectious pneumonitis and three with witnessed episodes of aspiration more than a decade ago as a biomarker of pulmonary infection. After admission, total serum calcitonin increased rapidly in all patients and progressively declined with clinical resolution. Interestingly, gel filtration chromatography confirmed at that time that the predominant circulating forms of calcitonin were the precursor forms, including PCT. No single cutoff, however, could be established that would separate the two entities from each other. Subsequently, the use of PCT as a diagnostic marker of gastric aspiration was investigated in 23 patients who presented with closed head injury (19) . Nine patients had evidence of aspiration of gastric content, defined as the presence of persistent infiltrates on chest x-ray in the first 24 hrs after admission and/or signs of aspiration on bronchoscopy. The initial serum PCT levels in these patients were significantly higher compared with those who had no evidence of aspiration. PCT was also significantly higher in nonsurvivors. However, the study did not look at the role of PCT in differentiating bacterial aspiration pneumonia from chemical aspiration pneumonitis.
Overall, the accuracy of PCT in diagnosing pneumonia in critically ill patients has been inconsistent (20 -22) . In fact, Luyt and colleagues (20) showed that for a cutoff of 0.5 ng/mL, PCT had a sensitivity of 72% and a specificity of 24% for the diagnosis of ventilator-associated pneumonia. Earlier, Gibot and coworkers (21) reported significant overlap in PCT levels between patients with ventilatorassociated pneumonia and those without pneumonia. Schuetz and colleagues (23) noted also in a retrospective study involving patients with therapeutic hypothermia after cardiac arrest that the increase in PCT was unspecific and paralleled the intensity of inflammatory reaction rather than the underlying infection. We found that the case for using PCT in pulmonary aspiration syndromes is no different. In our study population, there was a significant overlap in the levels of PCT in both BAL-positive and BAL-negative cultures making any distinction between the two entities unachievable. In few cases of aspiration with negative BAL cultures, the levels of PCT were much higher than those with documented bacterial infection. This disparity could be related to a time lag of 24 to 48 hrs, which can exist between onset of bacterial infection and peak PCT release (24) . Alternatively, acidrelated lung injury may result in instantaneous extravasation of calcitonin precursor eclipsing the rise of PCT in bacterial aspiration pneumonia.
Our study results are in line with previous investigations pointing to a significant association between decreasing levels of PCT and favorable outcome. Seligman and coworkers (25) showed that repeated measurement of PCT at onset and on the fourth day of treatment can predict survival in patients with ventilator-associated pneumonia. A drop in either PCT or C-reactive protein was indicative of lower mortality. Similarly, Luyt et al (26) established in a comparable population that serial PCT levels may provide an early indication of an unfavor- able outcome. In the absence of immediate therapeutic modality for aspiration, prognostic biomarkers can be used as a guide in triaging patients to a lower level of care, directing use of scare resources, and approaching patients for participating in clinical trials. We should be careful, however, from overstating the role of PCT in prognosticating outcome of patients with the aspiration syndromes until further validation studies are performed. More recently, PCT has been advocated as a clinical tool to guide antimicrobial therapy in patients presenting at the emergency department or for the treatment of lower respiratory tract infection (5, 6, 27, 28) . In a randomized controlled trial, Schuetz et al (5) demonstrated that administration of antibiotics based on serial PCT determination with predefined cutoff ranges for initiating or stopping antibiotics for lower respiratory tract infections reduced antibiotic use by 3 days. The reduction in antibiotic duration was achieved predominantly by early discontinuation of antibiotic therapy. In contrast, Stolz et al (6) reported a 27% reduction in duration of antibiotics in the PCT group mostly because the control group had received 15 days of antimicrobial therapy. Using a similar design, Bouadma and colleagues (9) extended these observations to patients with suspected infections on admission or during their stay in intensive care units. For patients in the PCT group, there was a 23% reduction in antibiotic exposure compared with the standard approach. However, there were several concerns about the design of the trial that pertained to the 10% noninferiority margin for mortality and the lack of adherence to the protocol in discontinuing antibiotic therapy. Whether a similar algorithmguided intervention can be developed for patients with suspected aspiration requires further investigations.
Some limitations of the study should be mentioned. In the absence of a "gold standard" diagnostic tool, the distinction between bacterial aspiration pneumonia and aspiration pneumonitis remains an arbitrary one. Even after relying on BAL cultures, the possibility of misclassification of either type of aspiration could have still occurred. Second, we have not measured BAL PCT because previous studies have suggested that the local production of PCT within the alveoli is limited (29, 30) and hence it plays a limited role in the diagnosis of lower respiratory tract infections. Third, the study population comprised patients with high acuity of disease requiring mechanical ventilation. It is plausible that the range of PCT values in less severely ill patients may be different from the one observed in this study. Furthermore, the study is limited by the inclusion of a control group of relatively small size with different baseline characteristics. Fourth, we have not assessed other biomarkers in the current study; however, previous investigations found C-reactive protein to be of limited value in aspiration syndromes (14, 31) . Fifth, we have not determined the costeffectiveness of routine PCT measurements. Pragmatic evidence of the comparative and cost-effectiveness of different point-of-care strategies is needed.
In conclusion, serum PCT may not be useful as a diagnostic marker of bacterial pulmonary aspiration. However, serial serum PCT may provide an early indication of outcome in pulmonary aspiration syndromes.
